Literature DB >> 32313192

Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan.

Shiori Nishimura1,2, Hiraku Kumamaru3, Satoshi Shoji4, Mitsuaki Sawano4, Shun Kohsaka4, Hiroaki Miyata1,2.   

Abstract

Nonadherence to antihypertensive drugs is a primary reason for suboptimal clinical outcomes among hypertensive patients. We assessed adherence to newly initiated antihypertensive medications in non-elderly Japanese patients and examined which patient and facility characteristics were associated with low adherence. We selected new oral antihypertensive drug users, aged 30-74 years, between 2014 and 2016 from a large administrative claims database. We measured adherence as the proportion of days covered (PDC) during a 1-year follow-up and divided patients into three groups of low (PDC < 40%), intermediate (PDC ≥ 40% to <80%), and high (PDC ≥ 80%) adherence. Factors associated with low adherence were assessed by logistic regression analysis with generalized estimating equations. Among 31,592 patients (mean age, 51.7 years; 41.2% female), the median 1-year PDC was 88.5% (IQR: 41.9-98.1%). In total, 59.2%, 16.6%, and 24.2% of patients were categorized as having high, intermediate, and low adherence, respectively. Female sex (odds ratio [OR] 1.15, 95% confidential interval [95% CI] 1.08-1.22), younger age, and the initiation of angiotensin-converting enzyme inhibitors (OR 1.37, 95% CI 1.12-1.66), beta-blockers and thiazide diuretics (OR 4.82, 95% CI 4.34-5.36 and OR 3.91, 95% CI 2.79-5.46, respectively; compared with angiotensin II receptor blockers) were associated with low adherence. Patients initiating antihypertensives at larger hospitals (≥200 beds) were more likely to be adherent. While adherence to antihypertensive drugs in non-elderly Japanese patients was relatively high compared with that reported in previous studies in Western countries, patients with intermediate-low adherence may benefit from targeted interventions.

Entities:  

Keywords:  Adherence; Antihypertensives; Claims data; Hypertension; Primary prevention

Year:  2020        PMID: 32313192     DOI: 10.1038/s41440-020-0440-2

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  29 in total

1.  Disparities in adherence to and persistence with antihypertensive regimens: an exploratory analysis from a community-based provider network.

Authors:  Denis Y Ishisaka; Trevor Jukes; Robert J Romanelli; Ken S Wong; Timothy A Schiro
Journal:  J Am Soc Hypertens       Date:  2012 May-Jun

Review 2.  Drug adherence in hypertension: from methodological issues to cardiovascular outcomes.

Authors:  Idir Hamdidouche; Vincent Jullien; Pierre Boutouyrie; Eliane Billaud; Michel Azizi; Stéphane Laurent
Journal:  J Hypertens       Date:  2017-06       Impact factor: 4.844

3.  Association Between Metformin Adherence and All-Cause Mortality Among New Users of Metformin: A Nested Case-Control Study.

Authors:  Patrice Simard; Nancy Presse; Louise Roy; Marc Dorais; Brian White-Guay; Agnès Räkel; Sylvie Perreault
Journal:  Ann Pharmacother       Date:  2017-11-16       Impact factor: 3.154

4.  Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients.

Authors:  Martin Schulz; Katrin Krueger; Katrin Schuessel; Kristina Friedland; Ulrich Laufs; Walter E Mueller; Miriam Ude
Journal:  Int J Cardiol       Date:  2016-06-29       Impact factor: 4.164

Review 5.  Epidemiology of hypertension in Japan: where are we now?

Authors:  Katsuyuki Miura; Masato Nagai; Takayoshi Ohkubo
Journal:  Circ J       Date:  2013-07-30       Impact factor: 2.993

6.  Medication Adherence and the Risk of Cardiovascular Mortality and Hospitalization Among Patients With Newly Prescribed Antihypertensive Medications.

Authors:  Soyeun Kim; Dong Wook Shin; Jae Moon Yun; Yunji Hwang; Sue K Park; Young-Jin Ko; BeLong Cho
Journal:  Hypertension       Date:  2016-01-25       Impact factor: 10.190

7.  Non-adherence to antihypertensive medication: The role of mental and physical comorbidity.

Authors:  Amaia Calderón-Larrañaga; Esperanza Diaz; Beatriz Poblador-Plou; Luis Andrés Gimeno-Feliu; José María Abad-Díez; Alexandra Prados-Torres
Journal:  Int J Cardiol       Date:  2016-01-11       Impact factor: 4.164

8.  Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.

Authors:  Giampiero Mazzaglia; Ettore Ambrosioni; Marianna Alacqua; Alessandro Filippi; Emiliano Sessa; Vincenzo Immordino; Claudio Borghi; Ovidio Brignoli; Achille P Caputi; Claudio Cricelli; Lorenzo G Mantovani
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

9.  Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario.

Authors:  Oded Friedman; Finlay A McAlister; Lingsong Yun; Norman R C Campbell; Karen Tu
Journal:  Am J Med       Date:  2010-02       Impact factor: 4.965

10.  Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Fatima Rodriguez; David J Maron; Joshua W Knowles; Salim S Virani; Shoutzu Lin; Paul A Heidenreich
Journal:  JAMA Cardiol       Date:  2019-03-01       Impact factor: 14.676

View more
  4 in total

1.  Researching on the compliance of epilepsy patients of the Phenobarbital Epilepsy Management Project in a rural area of China: A retrospective study.

Authors:  Xiang-Lin Feng; Bang-An Luo; Lu-Lu Qin
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

2.  Treatment and adherence to antihypertensive therapy in France: the roles of socioeconomic factors and primary care medicine in the ESTEBAN survey.

Authors:  Alexandre Vallée; Clémence Grave; Amélie Gabet; Jacques Blacher; Valérie Olié
Journal:  Hypertens Res       Date:  2021-01-14       Impact factor: 3.872

3.  Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.

Authors:  Luca Degli Esposti; Chiara Veronesi; Domenica Daniela Ancona; Margherita Andretta; Fausto Bartolini; Alberto Drei; Alessandro Lupi; Stefano Palcic; Davide Re; Francesca Vittoria Rizzi; Elisa Giacomini; Valentina Perrone
Journal:  Clinicoecon Outcomes Res       Date:  2022-03-10

4.  Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database.

Authors:  Ryuta Saito; Hiroyuki Yamamoto; Nao Ichihara; Hiraku Kumamaru; Shiori Nishimura; Koki Shimada; Kiyoshi Mori; Yoshiki Miyachi; Hiroaki Miyata
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.